Xenon Pharmaceuticals Revenue and Competitors

Location

$942.6M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Xenon Pharmaceuticals's estimated annual revenue is currently $68.8M per year.(i)
  • Xenon Pharmaceuticals received $63.0M in venture funding in September 2018.
  • Xenon Pharmaceuticals's estimated revenue per employee is $251,250
  • Xenon Pharmaceuticals's total funding is $942.6M.

Employee Data

  • Xenon Pharmaceuticals has 274 Employees.(i)
  • Xenon Pharmaceuticals grew their employee count by 18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$37M18430%N/AN/A
#2
$68.8M27418%$942.6MN/A
#3
$23.5M1170%N/AN/A
#4
$1.6M1645%$3.7MN/A
#5
$1.5M1515%N/AN/A
#6
$1.4M148%N/AN/A
#7
$0.7M7-56%N/AN/A
#8
$10.5M5218%N/AN/A
#9
$0.6M60%N/AN/A
#10
$0.5M50%$8.9MN/A
Add Company

XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. We apply our expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$942.6M

Total Funding

274

Number of Employees

$68.8M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Xenon Pharmaceuticals News

2022-04-17 - SVB Leerink Equities Analysts Raise Earnings Estimates for Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Rating) - Equities research analysts at SVB Leerink boosted their Q2 2022 earnings per share...

2022-04-17 - Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Analysts. Posted by admin on Apr 22nd, 2022.

2022-04-17 - Xenon Pharmaceuticals to Participate in Upcoming Investor ...

BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical...

2021-10-08 - Xenon Pharmaceuticals : Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sol ...

2021-10-08 - Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sol ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$61.3M27615%N/A
#2
$15M287N/AN/A
#3
$77.2M29340%$156M
#4
$32.5M2950%N/A
#5
$61M30531%N/A

Xenon Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2018-09-21$63.0MUndisclosedJefferies LLCArticle

Xenon Pharmaceuticals Executives


NameTitle
Chris Von SeggernChief Commercial Officer
Jonathan NeuChief Medical Officer
Ian MortimerPresident & CEO
Sherry AulinChief Financial Officer
Simon PimstonePresident and CEO
Chris Von SeggernChief Commercial Officer
Christopher KenneyChief Medical Officer
Shelley McCloskeySVP - Human Resources
Charles CohenVice President, Biology
Robin SherringtonExecutive Vice President, Strategy & Innovation
Sheila GrantSenior VP R&D Operations
Shelley McCloskeySenior Vice President, Human Resources
Ian MortimerPresident & CEO
James EmpfieldSr. VP, Drug Discovery
Bonnie FaustVP of Clinical Operations
Jay CadieuxVice President, Product Development & Operations
JP JohnsonVP, Biology
Simon PimstonePresident and CEO
Emmanuelle ValleeVP, Legal Affairs